SAVANNAH RESOURCES PLC
SAV | IL
Overview
Corporate Details
- ISIN(s):
- GB00B647W791
- LEI:
- 213800UCK16HW5KKGP60
- Country:
- United Kingdom
- Address:
- SALISBURY HOUSE, EC2M 5PS LONDON
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Scancell Holdings PLC, founded in 1997, develops innovative immunotherapies for cancer and infectious diseases.Ê Its mission is to create therapeutic cancer vaccines using vaccine platforms (Moditope, ImmunoBody) and monoclonal antibody platforms (GlyMab, AvidiMab) to stimulate the patient's immune system.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-28 08:00 |
Investor Presentation
Investor Presentation
|
English | 15.1 KB | |
| 2025-07-24 08:00 |
Capital/Financing Update
Appointment of Project Finance Advisor
|
English | 20.6 KB | |
| 2025-07-10 08:00 |
Investor Presentation
New Corporate Presentation
|
English | 15.0 KB | |
| 2025-07-02 08:00 |
Share Issue/Capital Change
Retail Offer increases Fundraise to £4.8 million
|
English | 28.3 KB | |
| 2025-06-27 08:20 |
Share Issue/Capital Change
Result of Accelerated Bookbuild and Subscription
|
English | 54.0 KB | |
| 2025-06-26 18:00 |
Share Issue/Capital Change
RetailBook Offer
|
English | 38.1 KB | |
| 2025-06-26 17:51 |
Share Issue/Capital Change
Proposed Fundraise
|
English | 147.2 KB | |
| 2025-06-18 14:27 |
Director's Dealing
PDMR Notification
|
English | 27.8 KB | |
| 2025-06-10 13:04 |
Post-Annual General Meeting Information
Result of AGM
|
English | 24.3 KB | |
| 2025-05-29 08:02 |
Earnings Release
More encouraging results in third batch of assays
|
English | 270.6 KB | |
| 2025-05-14 08:00 |
Report Publication Announcement
Research Initiation by Canaccord Genuity
|
English | 15.3 KB | |
| 2025-04-22 09:47 |
Major Shareholding Notification
Holding(s) in Company
|
English | 39.3 KB | |
| 2025-03-27 08:00 |
Regulatory News Service
Encouraging first assays from Phase 2 drilling
|
English | 185.0 KB | |
| 2025-03-25 16:58 |
Share Issue/Capital Change
BLP designated as Strategic Project under EU CRMA
|
English | 22.0 KB | |
| 2025-02-21 08:00 |
Legal Proceedings Report
Restart of fieldwork at Project
|
English | 17.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
CHOSA Oncology AB | Sweden | CHOSA | |
|
Cinclus Pharma Holding AB | Sweden | CINPHA | |
|
Circio Holding ASA | Norway | CRNA | |
|
CIZZLE BIOTECHNOLOGY HOLDINGS PLC | United Kingdom | CIZ | |
|
CLAL Biotechnology Industries Ltd. | Israel | CBI | |
|
Combigene AB | Sweden | COMBI | |
|
Compugen Ltd. | Israel | CGEN | |
|
Corline Biomedical AB | Sweden | CLBIO | |
| CRISM Therapeutics Corporation | Virgin Islands (British) | N/A | ||
|
Curasight A/S | Denmark | CURAS |